A new era in biotechnology dawns with IIT Roorkee’s launch of an advanced antibody discovery platform. Designed to combat cancer, infectious diseases, autoimmune disorders, and emerging threats, it rapidly uncovers antibodies that are not just effective but exceptionally stable and tightly bound to their targets.
At its core lies an expansive, diverse nanobody library—single-domain antibodies known for their resilience in harsh conditions. This enables faster screening and selection, filling a vital void in global health preparedness.
The implications are profound: shorter discovery phases mean swifter responses to outbreaks, more precise cancer treatments, and better management of chronic conditions. For nations like India, it’s a step toward affordable, accessible healthcare.
Prof. Rajesh Kumar, spearheading the project, noted: ‘This universal system empowers rapid disease countermeasures, prioritizing those in greatest need with cost-effective options.’
Perfectly in tune with Atmanirbhar Bharat, it enhances domestic R&D, minimizes import reliance, and promotes translational breakthroughs. Long-term, it fortifies pandemic readiness and public health systems.
IIT Director Prof. K.K. Pant underscored the collaborative triumph: ‘It shows the power of blending core research with practical goals and industry ties to overcome societal obstacles.’
Sealing the deal, an MoU with Imgenex India paves the way for shared advancements in biologics development, antibody engineering, diagnostics, and more. Together, they’re building a robust biotech ecosystem.
This innovation doesn’t just advance science—it’s a strategic asset for India’s health security, proving homegrown talent can lead global fights against disease.